MedTrace Logo

A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)

NCT01466647 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2012-11-12

No results posted yet for this study

Summary

This is a open single-center, explorative, Phase I pilot dose finding study including patients treated with AXL1717 in addition to standard chemotherapy of gemcitabine HCL and carboplatin.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

AXL1717

A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods

Sponsors & Collaborators

  • Axelar AB

    lead INDUSTRY

Principal Investigators

  • Michael Bergqvist, M.D., Ph.D · Uppsala University Hospital, Sweden

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01466647 on ClinicalTrials.gov